Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_US)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MobiusHD™
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Carotid Sinus
Eligibility Criteria
Inclusion Criteria:
- Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic. Any combination medications will be counted per the active ingredient. (For example, Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)
Exclusion Criteria:
- Known or clinically suspected baroreflex failure or autonomic neuropathy
Sites / Locations
- Cardiology, P.C.
- Emory University
- Iowa Heart Center
- Ochsner Clinic Foundation
- University of Rochester
- The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital
- Turkey Creek Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MobiusHD™
Arm Description
MobiusHD™
Outcomes
Primary Outcome Measures
Adverse Events
Number of Participants with Adverse Events
Secondary Outcome Measures
Change in Systolic Office Blood Pressure (OBP)
Change in Systolic Office Blood Pressure (OBP) compared to baseline.
Change in Systolic Ambulatory Blood Pressure (ABPM)
Change in Systolic Ambulatory Blood Pressure (ABPM) measured at 3 and 6 months compared to baseline values.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01831895
Brief Title
Controlling and Lowering Blood Pressure With The MOBIUSHD™
Acronym
CALM-FIM_US
Official Title
CALM-FIM_US -Controlling and Lowering Blood Pressure With the MobiusHD™ - A Prospective Multicenter Safety Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
May 2013 (Actual)
Primary Completion Date
July 8, 2020 (Actual)
Study Completion Date
April 13, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vascular Dynamics, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.
Detailed Description
This is an open-label, multicenter, first-in-man clinical trial to be conducted inside the United States. Eligible subjects with stage 2 resistant systemic arterial hypertension currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the MobiusHD system.
Potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo placement of the MobiusHD under angiographic visualization, and will then be followed for 36 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Carotid Sinus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
17 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MobiusHD™
Arm Type
Experimental
Arm Description
MobiusHD™
Intervention Type
Device
Intervention Name(s)
MobiusHD™
Intervention Description
Implant that is placed in the carotid sinus to control hypertension.
Primary Outcome Measure Information:
Title
Adverse Events
Description
Number of Participants with Adverse Events
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Change in Systolic Office Blood Pressure (OBP)
Description
Change in Systolic Office Blood Pressure (OBP) compared to baseline.
Time Frame
3 years
Title
Change in Systolic Ambulatory Blood Pressure (ABPM)
Description
Change in Systolic Ambulatory Blood Pressure (ABPM) measured at 3 and 6 months compared to baseline values.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic. Any combination medications will be counted per the active ingredient. (For example, Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)
Exclusion Criteria:
Known or clinically suspected baroreflex failure or autonomic neuropathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark C Bates, MD
Organizational Affiliation
West Virginia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiology, P.C.
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35211
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
Facility Name
Iowa Heart Center
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50309
Country
United States
Facility Name
Ochsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14627
Country
United States
Facility Name
The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Turkey Creek Medical Center
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37934
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
35144789
Citation
van Kleef MEAM, Devireddy CM, van der Heyden J, Bates MC, Bakris GL, Stone GW, Williams B, Spiering W; CALM-FIM Investigators. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 Feb 14;15(3):321-332. doi: 10.1016/j.jcin.2021.12.015.
Results Reference
derived
Learn more about this trial
Controlling and Lowering Blood Pressure With The MOBIUSHD™
We'll reach out to this number within 24 hrs